Sellas Life Sciences Group Clinical Trial Data
SELLAS announced positive topline results from its pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival, showing a 41% reduction in the risk of death with a median OS of 24.0 months for GPS versus 14.7 months for best available treatment. The company plans to meet with the FDA to discuss the regulatory path forward for a Biologics License Application (BLA) submission.